PRISM Services™
Prevalence Reconstruction & Integrated Systems Modeling

Accurate population estimates influence how chronic conditions are researched, funded, diagnosed, and treated. Yet many rare, ultra-rare, and historically underrecognized conditions continue to rely on prevalence figures that may not fully account for diagnostic limitations, healthcare disparities, specialist shortages, or changing population trends. Even well-established conditions may require reassessment as environmental volatility and infection-associated complications contribute to increased healthcare demand and changes in clinical presentation.
PRISM Services™ helps nonprofits, patient organizations, research foundations, and institutions investigate these gaps through condition-specific population analysis, scientific research development, and institutional funding strategy. Using the proprietary Prevalence Reconstruction & Integrated Systems Modeling framework, we examine available epidemiological evidence alongside diagnostic capture, clinical recognition, healthcare access, and relevant demographic differences to develop transparent population estimates and supporting research materials.
Our work extends beyond calculating prevalence. Organizations can commission comprehensive white papers, publication-ready research materials, congressional funding briefs, and evidence supporting expanded research programs, physician education, diagnostic access initiatives, and specialist training. These materials can also strengthen foundation proposals, institutional partnerships, and organizational fundraising by providing documented evidence of unmet needs and research priorities.
From Population Research to Funding Opportunities
When existing estimates do not adequately represent the number of people living with a condition, research priorities and funding requests may need to be reconsidered. Similarly, an established condition experiencing increased clinical complexity, specialist demand, or diagnostic delays may require additional investment in research and physician education even when its overall prevalence remains relatively stable.
PRISM helps organizations evaluate these questions using available data and condition-specific methodologies rather than relying exclusively on individual patient experiences. Where supported, analysis may incorporate race-stratified estimates, diagnostic recognition gaps, overlapping patient populations, and changes associated with post-infection conditions. Findings can inform funding requests addressing scientific research, continuing medical education, diagnostic access, and the clinical resources needed to improve care.
CYNAERA Institute can also support the publication and discoverability of commissioned research through our ACE™ and RAVE™ methodologies. This approach helps organizations prepare credible evidence for scientific audiences, AI-assisted research discovery, policymakers, and institutional collaborators. Our own research has demonstrated sustained organic discoverability, including the appearance of CYNAERA Institute's ME/CFS prevalence estimates in AI search results before their subsequent citation in a National Institutes of Health research resource. The objective is to make research evidence easier to find, understand, and use while maintaining clear distinctions between published findings, modeled estimates, and scientific validation.
PRISM Services™ Process
PRISM Services offers three fixed-price research packages designed to help organizations evaluate population estimates, develop scientific evidence, and prepare institutional funding requests. Each package includes clearly defined deliverables so organizations can plan their budgets, obtain board approval, and commission research without uncertainty about the cost.
PRISM Services are fixed-price, independently conducted research engagements developed using CYNAERA's proprietary analytical frameworks. Each package includes the research and deliverables described at the time of purchase, with no required subscriptions, recurring fees, or client-directed revision rounds. CYNAERA independently determines the appropriate methodology, evaluates the available evidence, and presents its findings regardless of whether the results support the client's anticipated conclusions. Factual or technical errors identified after delivery will be addressed by CYNAERA as appropriate.
PRISM Prevalence Assessment - $7,500
This assessment examines existing prevalence estimates for one condition and one defined population, including diagnostic and reporting limitations, relevant research gaps, and opportunities for population reconstruction. In only 24 hours, organizations receive a written assessment, of the available evidence, preliminary findings, and recommendations for additional research. The package is designed for organizations evaluating whether a more comprehensive analysis would support their current research priorities.
PRISM Research & Funding Evidence Package - $35,000
This package provides a comprehensive prevalence analysis for one condition and one defined population, incorporating relevant source evaluation, diagnostic capture assessment, and population reconstruction where supported by available evidence. In only 72 hours, you will receive a technical white paper, a publication-ready preprint manuscript, an institutional research funding brief, and ACE™/RAVE™ discoverability recommendations to support research visibility and attribution. The completed materials can be used in congressional meetings, foundation proposals, scientific collaborations, and organizational research planning.
PRISM Advanced Population & Institutional Funding Architecture - $65,000
This package includes the comprehensive research and funding materials from the preceding service, with expanded analysis of demographic differences, special populations, diagnostic recognition, specialist access, and physician education needs. Within 5 business days organizations receive an advanced technical white paper, a publication-ready preprint manuscript, an expanded institutional funding brief, and a proposed funding framework addressing research, clinical education, and relevant diagnostic access priorities. Where supported by the evidence, the analysis can also evaluate overlapping patient populations and changing prevalence estimates.
Research That Supports Your Next Steps
CYNAERA maintains a developing chronic-condition prevalence database containing approximately 1,000 preliminary condition entries, supported by a broader portfolio of epidemiological, diagnostic, and population intelligence methodologies. This infrastructure allows us to approach new research questions using existing analytical foundations while evaluating the evidence and limitations unique to each condition. PRISM Services supports rare, ultra-rare, autoimmune, neurological, infection-associated, and other chronic conditions, including established patient communities reassessing their research and healthcare needs. Our analyses are designed to provide evidence that organizations can use across research planning, funding discussions, publication, and institutional engagement.
Commissioned findings remain independent of the funding outcome sought. CYNAERA does not guarantee increased prevalence estimates, publication acceptance, AI citations, or funding awards. Organizations receive agreed rights to use their completed research deliverables while CYNAERA retains ownership of its underlying proprietary methodologies and technologies. Whether your organization is preparing its first major research funding request or reassessing the needs of an established patient population, PRISM Services provides the analytical foundation to make a more informed case for investment.
Delivery Times
The PRISM Prevalence Assessment™ is delivered within 24 hours, the PRISM Research & Funding Evidence Package™ within 72 hours, and the PRISM Advanced Population & Institutional Funding Architecture™ within 5 business days after payment confirmation and receipt of the required research information. Additional verification of epidemiological sources, population definitions, or submitted data may affect when the delivery period begins. All analyses are conducted remotely using available research, relevant population data, and CYNAERA's proprietary methodologies, with completed reports and supporting materials delivered electronically in English. The scope and depth of the analysis depend on the selected package and the availability of reliable evidence. External publication, peer review, and indexing timelines are not included in the stated delivery periods.
Frequently Asked Questions
What is PRISM Services™?
PRISM Services™ is CYNAERA's commissioned research service built around Prevalence Reconstruction & Integrated Systems Modeling. It helps organizations evaluate population estimates, investigate diagnostic and reporting gaps, and develop research materials that support institutional funding requests, scientific collaboration, and strategic planning. Services range from focused prevalence assessments to comprehensive research and funding packages.
What types of organizations can use PRISM Services?
PRISM Services is available to patient organizations, nonprofits, research foundations, academic institutions, healthcare organizations, professional associations, and research coalitions. Services can support organizations representing rare, ultra-rare, and well-established chronic conditions, including those seeking updated population estimates or stronger evidence for research and clinical education investments.
Can PRISM analyze conditions that already have established prevalence estimates?
Yes. Established prevalence figures may warrant reassessment when new epidemiological findings, changing diagnostic practices, demographic trends, or infection-associated complications affect population estimates. PRISM evaluates the available evidence to determine whether existing figures remain appropriate rather than automatically assuming a higher estimate is needed.
Can PRISM incorporate our organization's existing research or patient data?
Yes. Organizations may provide published research, aggregate patient data, registry findings, surveys, or other relevant documentation for consideration. CYNAERA evaluates the quality, compatibility, and relevance of submitted information before determining how it can be incorporated into the analysis. Additional data requirements depend on the selected package, and organizations should not submit identifiable patient records unless a separate appropriate data arrangement has been established.
Can PRISM analyze demographic differences or special populations?
Yes. The Advanced Population & Institutional Funding Architecture package can evaluate demographic differences, special populations, diagnostic recognition, and healthcare access when sufficient evidence is available. Analyses may include age groups, geographic populations, veterans, pediatric populations, or other relevant groups, depending on the organization's research objectives.
How can PRISM support congressional research funding requests?
PRISM can develop population estimates, technical research materials, funding-gap analyses, and institutional briefing documents that help organizations explain the need for additional research investment. Depending on the package, findings may also support proposed funding for physician education, diagnostic improvements, specialist training, and related research infrastructure. CYNAERA provides independent analytical evidence and does not guarantee legislative action or funding approval.
Can our organization use the completed research for fundraising?
Yes. Organizations may use their completed research and approved briefing materials within the rights provided by their service agreement to support foundation applications, donor communications, research partnerships, and organizational fundraising. These materials can help communicate the organization's contribution to advancing research priorities without requiring it to claim outcomes that have not occurred.
Does PRISM include a white paper or publication support?
The Research & Funding Evidence Package and Advanced Population & Institutional Funding Architecture package include a technical white paper and publication-ready preprint manuscript. These materials are prepared for independent research dissemination and may support future journal submissions. External publication acceptance, peer review, and repository processing remain subject to the policies and timelines of the receiving publication or platform.
Will PRISM help our research appear in AI-generated search results?
Applicable packages include research discoverability and attribution recommendations informed by CYNAERA's ACE™ and RAVE™ methodologies. These can help organizations improve how their research is structured, published, and represented across digital information systems. However, search engines and AI platforms independently determine their results, so specific rankings, citations, and indexing outcomes cannot be guaranteed.
How much does PRISM Services cost?
PRISM Services offers three fixed-price packages: the Prevalence Assessment for $7,500, the Research & Funding Evidence Package for $35,000, and the Advanced Population & Institutional Funding Architecture package for $65,000. Each price covers the defined package deliverables, with no required subscriptions or recurring service fees. Additional conditions or work outside the selected package are commissioned separately.
How quickly will we receive our research?
The PRISM Prevalence Assessment is delivered within 24 hours, the Research & Funding Evidence Package within 72 hours, and the Advanced Population & Institutional Funding Architecture package within 5 business days after payment confirmation and receipt of the required research information. Additional source or data verification may affect when the delivery period begins. Completed materials are delivered electronically in English, and external publication timelines are not included.
Can we request changes to the research findings?
PRISM Services provides independent scientific analysis using CYNAERA's proprietary methodologies. Clients purchase the completed research and defined deliverables rather than directing the methodology or conclusions, so packages do not include client-directed revision rounds. Any identified factual or technical errors are evaluated by CYNAERA and corrected when appropriate.
Who owns the completed research and underlying methodologies?
Organizations receive the agreed rights to use and distribute their completed research reports, white papers, and institutional briefing materials. CYNAERA retains ownership of its pre-existing proprietary methodologies, modeling frameworks, software, templates, and related intellectual property. Separate institutional licensing arrangements are available for organizations seeking broader implementation rights.
Does PRISM guarantee a higher prevalence estimate or additional research funding?
No. PRISM evaluates the available evidence independently and may confirm an existing estimate, identify a supported adjustment, or determine that additional research is necessary. Its findings are designed to strengthen the information available for research planning and funding decisions, but CYNAERA does not guarantee increased estimates, congressional appropriations, research grants, or institutional adoption.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including ACE™, RAVE™, CRATE™, SymCas™, TrialSim™, and BRAGS™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs. CYNAERA was built as an integration-first infrastructure platform, prioritizing interoperability and acquisition readiness over venture funding cycles.



